JGC
CPIX icon

J. Goldman & Co’s Cumberland Pharmaceuticals CPIX Stock Holding History

J. Goldman & Co’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$263K Sell
81,040
-13,501
-14% -$52K 0.01% 579
2025
Q4 		$376K Sell
94,541
-113,602
-55% -$337K 0.01% 477
2025
Q3 		$649K Sell
208,143
-12,564
-6% -$41.7K 0.02% 365
2025
Q2 		$739K Sell
220,707
-20,774
-9% -$98.4K 0.02% 356
2025
Q1 		$1.02M Buy
+241,481
New +$1M 0.03% 363

Other funds holding CPIX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

J. Goldman & Co's CPIX Position: Q1 2026 in Review

J. Goldman & Co reduced its Cumberland Pharmaceuticals (CPIX) stake by 14% in Q1 2026, selling an estimated $52K and leaving 81,040 shares worth $263K. The position accounts for 0.01% of the portfolio, ranked #579.

J. Goldman & Co first reported a position in CPIX in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.02M in Q1 2025. 29 funds tracked by Wall St. Rank hold CPIX as of Q1 2026.

  • J. Goldman & Co held 81,040 shares of Cumberland Pharmaceuticals worth $263K as of Q1 2026.
  • J. Goldman & Co sold 13,501 Cumberland Pharmaceuticals shares in Q1 2026, an estimated $52K.
  • Cumberland Pharmaceuticals made up 0.01% of J. Goldman & Co's portfolio in Q1 2026, its #579 holding.
  • J. Goldman & Co first reported a position in Cumberland Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • J. Goldman & Co's Cumberland Pharmaceuticals position peaked at $1.02M in Q1 2025.
  • 29 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.